{"product_id":"macrogenics-five-forces-analysis","title":"MacroGenics Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eMacroGenics faces strong buyer bargaining and intense rivalry due to concentrated payor influence and competing immunotherapy players, while supplier power and substitute threats remain moderate as biologics manufacturing and novel modalities evolve.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore MacroGenics’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Contract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics relies on a few specialized Contract Development and Manufacturing Organizations (CDMOs) to make its DART bispecifics, giving suppliers strong leverage; industry data shows top mammalian-cell CDMO capacity utilization at ~85% in 2024, tightening availability. Switching sites triggers costly regulatory re-validation and comparability studies often exceeding $20–50M and 12–24 months, so MacroGenics faces high switching costs and supplier bargaining power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCritical Raw Materials and Cell Lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics relies on single-sourced proprietary cell lines and high-grade reagents; suppliers of media and biologics can push prices and delivery terms, constraining margins—biologics input costs represent ~15–25% of COGS in mid-size oncology biotechs (2024 data).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHighly Skilled Scientific Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe niche expertise in bispecific antibody engineering means supply of skilled researchers and clinical trial managers is scarce, raising supplier (labor) leverage; a 2024 BioPharma survey found 62% of firms report talent shortages in biologics R\u0026amp;D. Competition from Big Pharma and well-funded startups drives salaries up—median biotech R\u0026amp;D lead pay rose ~14% from 2021–2024—so retaining staff is critical for MacroGenics’ competitive edge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMacroGenics relies on third-party Clinical Research Organizations (CROs) to run multi-site global trials; in 2024 CROs handled ~70% of late-stage biologics trial operations, a scale mid-sized biotechs can’t match internally.\u003c\/p\u003e\n\u003cp\u003eCROs drive timing and data quality—delays or protocol deviations can push FDA filings back months, affecting Macrogenics’ cash burn and milestones tied to potential $100M+ licensing payments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh dependence: CROs provide unique patient networks\u003c\/li\u003e\n\u003cli\u003eSwitch cost: replacing CROs delays trials by months\u003c\/li\u003e\n\u003cli\u003eNegotiation leverage: CRO demand rose 8–12% in 2023–24\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Licensing Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMacroGenics owns the DART platform but often licenses key components from universities or biotech partners; licensors can demand royalties and milestone fees that reduce long-term margins—typical biotech royalty rates range 2–10% and milestone payments can exceed $5m–$50m per program.\u003c\/p\u003e\n\u003cp\u003eWhen licensed tech is critical to a lead candidate, MacroGenics has limited leverage in negotiations, raising risk to EBITDA and deal economics—losing access or facing higher fees can delay commercialization and cut net returns.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRoyalty range: 2–10%\u003c\/li\u003e\n\u003cli\u003eMilestones: often $5m–$50m+ per program\u003c\/li\u003e\n\u003cli\u003eFoundational tech reduces MacroGenics bargaining leverage\u003c\/li\u003e\n\u003cli\u003eHigher fees directly compress long-term profitability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier squeeze: high CDMO\/CRO costs, royalties and milestones compress MacroGenics margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics faces high supplier power: CDMO capacity ~85% utilized (2024), site switches cost $20–50M and 12–24 months, biologics inputs = 15–25% of COGS, CROs run ~70% late-stage ops and raised fees 8–12% (2023–24), royalties 2–10% and milestones $5–50M compress margins and raise EBITDA risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024 Stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO utilization\u003c\/td\u003e\n\u003ctd\u003e~85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitch cost\/time\u003c\/td\u003e\n\u003ctd\u003e$20–50M \/ 12–24m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiologics input share\u003c\/td\u003e\n\u003ctd\u003e15–25% of COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO share late-stage\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO fee change\u003c\/td\u003e\n\u003ctd\u003e+8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalty range\u003c\/td\u003e\n\u003ctd\u003e2–10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestones\u003c\/td\u003e\n\u003ctd\u003e$5–50M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter's Five Forces analysis for MacroGenics uncovering competitive intensity, buyer\/supplier power, entry barriers, substitution threats, and industry rivalry with strategic commentary and actionable insights to inform investor and management decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces one-sheet tailored for MacroGenics—quickly highlights competitive pressures and strategic levers to inform licensing, partnership, or pipeline decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated Payer Influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConcentrated payer influence means government and private insurers set reimbursement and can push for lower prices or formulary exclusion if MacroGenics’ cancer drugs don’t beat existing care; in 2024 Medicare Part B\/Part D and major US insurers covered ~80% of oncology spend and increasingly require cost-effectiveness evidence (ICER thresholds around $100–$150k\/QALY) and real-world outcomes, so MacroGenics must prove superior clinical benefit and value to secure access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Pharmaceutical Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStrategic pharmaceutical partners like Pfizer and GSK (examples of big pharma collaborators) exert high bargaining power over MacroGenics because they supply capital and global commercial networks in exchange for development control; MacroGenics reported 2024 collaboration revenue of $120.4m, underscoring reliance on partners. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals and Oncology Purchasing Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge U.S. hospital systems and GPOs (group purchasing organizations) like Vizient and Premier control roughly 40–60% of acute-care purchasing; they negotiate deep volume discounts that squeeze supplier margins and demand rebates. \u003c\/p\u003e\n\u003cp\u003eThese buyers shape oncology formularies and clinical pathways—GPO inclusion can drive adoption; exclusion often limits uptake to niche centers. \u003c\/p\u003e\n\u003cp\u003eIn 2024, GPO-negotiated contracts covered \u0026gt;70% of hospital oncology spend, so missing those contracts would materially cap MacroGenics’ market penetration and revenue potential. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePatient advocacy groups in oncology push hard on pricing and access; campaigns helped secure a Medicare Part B reimbursement change in 2023 that affected monoclonal antibody revenues, and 62% of surveyed US cancer patient groups said affordability was their top policy demand in 2024.\u003c\/p\u003e\n\u003cp\u003eThey back approvals but demand transparency and patient access programs; their media pressure can shift FDA review timelines and shape payer coverage, affecting peak sales forecasts for MacroGenics antibody candidates (typical impact ±10–25%).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e62% of US cancer groups prioritize affordability (2024 survey)\u003c\/li\u003e\n\u003cli\u003e2023 Medicare Part B change influenced antibody reimbursement\u003c\/li\u003e\n\u003cli\u003eAdvocacy can alter approval\/coverage, moving peak sales ±10–25%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic Medical Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLeading academic medical centers act as customers and key opinion leaders; their endorsement via trials and peer-reviewed papers can make or break uptake of MacroGenics’ DART platform.\u003c\/p\u003e\n\u003cp\u003eIndependent validation matters: 2024 shows top 20 US AMCs account for roughly 35% of NIH clinical trial sites; lack of traction there can cut commercial adoption and payer support.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAMCs = customers + validators\u003c\/li\u003e\n\u003cli\u003eTop 20 AMCs ≈35% of NIH trial activity (2024)\u003c\/li\u003e\n\u003cli\u003ePeer-reviewed validation drives clinician and payer adoption\u003c\/li\u003e\n\u003cli\u003eNo AMC traction risks stalled commercialization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers wield power: payers, GPOs, partners, AMCs \u0026amp; patients shape oncology pricing and access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers—payers, GPOs\/hospitals, pharma partners, AMCs, and patient groups—hold high bargaining power: payers (Medicare Part B\/D + major insurers ≈80% oncology spend in 2024) push ICER-like $100–$150k\/QALY thresholds; GPOs cover \u0026gt;70% hospital oncology spend and negotiate deep discounts; MacroGenics’ 2024 collaboration revenue $120.4m shows partner dependence; AMC trial influence (~35% NIH sites top20) and patient advocacy (62% demand affordability) affect access and peak sales ±10–25%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBuyer\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003e≈80% oncology spend; $100–$150k\/QALY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPOs\/hospitals\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70% hospital oncology spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma partners\u003c\/td\u003e\n\u003ctd\u003eMacroGenics collaboration rev $120.4m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMCs\u003c\/td\u003e\n\u003ctd\u003eTop20 ≈35% NIH trial sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient groups\u003c\/td\u003e\n\u003ctd\u003e62% cite affordability; impact ±10–25% sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eMacroGenics Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Porter’s Five Forces analysis of MacroGenics you’ll receive immediately after purchase—no placeholders, no mockups.\u003c\/p\u003e\n\u003cp\u003eThe document displayed here is the final, fully formatted deliverable—ready for download and use the moment you buy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747263525241,"sku":"macrogenics-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/macrogenics-five-forces-analysis.png?v=1772196812","url":"https:\/\/growthsharematrix.com\/products\/macrogenics-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}